
The Science of Gene Therapy for Hemophilia
Re-certified for CME credits, to Sept 6, 2020! The third activity in the Clinical Advances in Gene Therapy for Hemophilia
Year: 2022
Language: Italian
Author(s): World Federation of Hemophilia
Format: Document
This document is an introductory guide to the World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR). It answers basic questions about the registry, its purpose, and what participants can expect. The guide is designed to help those who receive gene therapy for hemophilia and their care teams to decide if they should participate in the registry.
Please reach out to WFH with questions regarding participation in the registry at [email protected].
This guide is also available in: English, French, Spanish
DOCUMENTS AND PDFS
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

Re-certified for CME credits, to Sept 6, 2020! The third activity in the Clinical Advances in Gene Therapy for Hemophilia

The second activity in the Clinical Advances in Gene Therapy for Hemophilia CME curriculum, Gene Therapy: Past, Present, and Future,

The first activity in the Clinical Advances in Gene Therapy for Hemophilia CME curriculum, Test Your Knowledge of Gene Therapy

In the Tuesday morning session on gene therapy, Christopher B. Doering presents advances in stem cell gene therapy of hemophilia